Amylyx Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Mar 3, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 3, 2026

AMLX$30.21+2.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share data)

	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$226,651	$77,391
Marketable securities	90,328	99,110
Accounts receivable, net	88	447
Prepaid expenses and other current assets	6,604	12,484
Total current assets	323,671	189,432
Property and equipment, net	310	961
Restricted cash equivalents	985	1,446
Operating lease right-of-use assets	5,181	1,771
Deposits and other assets	2,498	24
Total assets	$332,645	$193,634
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$3,519	$2,939
Accrued expenses	17,910	23,949
Operating lease liabilities, current portion	1,259	1,518
Total current liabilities	22,688	28,406
Operating lease liabilities, net of current portion	4,698	463
Total liabilities	27,386	28,869
Commitments and contingencies (Note 16)
Stockholders’ equity:
Common stock, $0.0001 par value; 300,000,000 shares authorized; 109,884,502 and 68,629,738 shares issued and outstanding as of December 31, 2025 and 2024, respectively	11	7
Additional paid-in capital	1,056,271	771,542
Accumulated deficit	(751,427)	(606,692)
Accumulated other comprehensive income (loss)	404	(92)
Total stockholders’ equity	305,259	164,765
Total liabilities and stockholders' equity	$332,645	$193,634

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.